Abstract:The opportunistic bacterial pathogen Pseudomonas aeruginosa causes a wide range of infections that are difficult to treat, largely because of the spread of antibiotic-resistant isolates. Antivirulence therapy, í . e . the use of drugs that inhibit the expression or activity of virulence factors, is currently considered an attractive strategy to reduce P . aeruginosa pathogenicity and complement antibiotic treatments. Because of the multifactorial nature of P . aeruginosa virulence and the broad arsenal of virulence factors this bacterium can produce, the regulatory networks that control the expression of multiple virulence traits have been extensively explored as potential targets for antivirulence drug development. The intracellular signaling molecule diadenosine tetraphosphate (Ap4A) has been reported to control stress resistance and virulence-related traits in some bacteria, but its role has not been investigated in P . aeruginosa so far. To fill this gap, we generated a mutant of the reference strain P . aeruginosa PAO1 that lacks the Ap4A-hydrolysing enzyme ApaH and, consequently, accumulates high intracellular levels of Ap4A. Phenotypic and transcriptomic analyses revealed that the lack of ApaH causes a drastic reduction in the expression of several virulence factors, including extracellular proteases, elastases, siderophores, and quorum sensing signal molecules. Accordingly, infection assays in plant and animal models demonstrated that ApaH-deficient cells are significantly impaired in infectivity and persistence in different hosts, including mice. Finally, deletion of apaH in P . aeruginosa clinical isolates demonstrated that the positive effect of ApaH on the production of virulence-related traits and on infectivity is conserved in P . aeruginosa . This study provides the first evidence that the Ap4A-hydrolysing enzyme ApaH is important for P . aeruginosa virulence, highlighting this protein as a novel potential target for antivirulence therapies against P . aeruginosa . Novel therapeutic interventions are urgently needed to address the threat of antimicrobial resistance. Inhibition of the virulence potential of bacterial pathogens, the so called antivirulence approach, is an alternative or complementary strategy to standard antibiotic-based therapies. The identification of suitable targets is essential to promote and advance antivirulence drug discovery programs. By combining in vitro analyses and in vivo infection assays, we demonstrated that the enzyme ApaH, which is responsible for the degradation of the intracellular signaling molecule diadenosine tetraphosphate, contributes to the virulence of the important human pathogen Pseudomonas aeruginosa . Indeed, loss of ApaH drastically reduces the production of several virulence factors in both laboratory and clinical isolates, and impairs P . aeruginosa ability to cause infection in plant, insect and rodent models. These results, together with the absence of ApaH homologues in mammals, make ApaH a promising target for the development of anti- P . aeruginosa antivirulence drugs.

Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System

Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance

The Type III Secretion System Facilitates Systemic Infections of Pseudomonas Aeruginosa in the Clinic.

Modulation of the immune response by the Pseudomonas aeruginosa type-III secretion system

Neutralizing human monoclonal antibodies that target the PcrV component of the Type III Secretion System of Pseudomonas aeruginosa act through distinct mechanisms

Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components

Innovative Approaches to Suppressing Pseudomonas aeruginosa Growth and Virulence: Current Status and Future Directions

Antivirulence therapy: type IV pilus as a druggable target for bacterial infections

Transcriptional Regulators Controlling Virulence in Pseudomonas aeruginosa

Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria

Pseudomonas aeruginosa Citrate Synthase GltA Influences Antibiotic Tolerance and the Type III Secretion System through the Stringent Response

A Supramolecular Antibiotic Targeting Drug-Resistant Pseudomonas aeruginosa through the Inhibition of Virulence Factors and Activation of Acquired Immunity

Novel drug targets in cell wall biosynthesis exploited by gene disruption in Pseudomonas aeruginosa

A Type VI Secretion System Trans-Kingdom Effector Is Required for the Delivery of a Novel Antibacterial Toxin in Pseudomonas aeruginosa

The diadenosine tetraphosphate hydrolase ApaH contributes to Pseudomonas aeruginosa pathogenicity

Pseudomonas aeruginosa two-component system CprRS regulates HigBA expression and bacterial cytotoxicity in response to LL-37 stress

A Novel Source of Tannic Acid Inhibiting Virulence and Quorum Sensing of Extensively Drug-Resistant Pseudomonas aeruginosa

Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant Pseudomonas aeruginosa

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Advances in Development of Novel Therapeutic Strategies against Multi-Drug Resistant Pseudomonas aeruginosa

A Potent Anti-Spue Antibody Allosterically Inhibits Type III Secretion System and Attenuates Virulence of Pseudomonas Aeruginosa.